Skip to main content
Equibles
HRTX logo

HRTX · Heron Therapeutics, Inc. /De/

Track HRTX — free

Use HRTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about HRTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.34 +0.00 (+0.69%) At close · Aug 14
Market Cap
$63.92M
Shares
189.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.34 Open$0.34 Day$0.33–0.35 52W close$0.32–1.49 Avg vol 30d2.8M Short int43.2M · 22.8% float · 24.4d Short vol62% Last earningsAug 10, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 8, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −64%
      below
      Price vs 50-day avg −23%
      below
      RSI (14) 28
      oversold
      MACD trend Negative
      52-week position 1%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −28%
      trailing
      6-month return −72%
      trailing
      YTD return −74%
      this year
      Relative strength −85%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +20 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      22.78% of float · ▲ +1.4% MoM · 24.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      162 holders — mid 3-yr range
      Squeeze score 71
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth +7%
      Y/Y
      Gross margin 73%
      expanding
      EPS growth −33%
      Y/Y
      Free cash flow $-27.9M
      Balance sheet $28.6M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 84%
      annualized · 1-yr
      Max drawdown −78%
      past year
      ATR 12.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 11, 2026
      Net Revenue · 2026 Full-Year $173M – $183M
      Adjusted EBITDA · 2026 Full-Year $10M – $20M
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2024
      Net revenue · Q4 2024 $37M – $43M
      Net revenue · Q4 2024 $37M – $43M
      Guided vs delivered · last 1 settled
      Revenue 2024
      guided $138M – $158M
      $144.29M In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −64% Bearish
      Price vs 50-day avg
      −23% Bearish
      RSI (14)
      28 Neutral
      MACD trend
      Negative Bearish
      52-week position
      1% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $0 › 200d $1 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +20 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      22.78% of float · ▲ +1.4% MoM · 24.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      162 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $0 Now $0 · 1% Range high $1
      vs 200-day avg -64% vs 50-day avg -23%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP 2.52M Six Months Ended June 30, 2026 —
      Average Daily Units 70% Q1 2026 —
      CINVANTI market share in the NK1 CINV category 25% Q1 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HRTX
      Heron Therapeutics, Inc. /De/
      this stock
      		$63.92M -74.1% +7.4% — 22.8%
      ONC
      BeOne Medicines Ltd.
      		 $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      		 $52.94B +1.2% — — 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      162
      % held
      72.1%
      Net QoQ
      -23.2M sh
      Top holder
      Rubric Capital Management…
      Held Float
      View
      Held by Funds
      Fund positions
      116
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      43.2M
      Days to cover
      24.4d
      Change
      +612.5K sh
      View
      Short Volume
      Short vol %
      62%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.6K
      Value
      $2.4K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      56.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Ashley Hinson Arenholz
      Amount
      $1.0K–$15.0K
      Traded
      Mar 31, 2021
      View
      Financials
      Financials
      Net income (FY)
      $-20.0M
      EPS diluted
      $-0.12
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 14, 2026
      This year
      14
      View
      Exempt Offerings
      Offering
      $30.0M
      Filed
      Aug 1, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 10, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      HRTX -31.3% -28.4% -71.7% -32.7% -74.1%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -31.7% -32.8% -85.5% -36.6% -88.0%
      Key facts CIK 818033 CUSIP 427746102 13F (30d) 154 filings 154 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)